Business UpdateJun 8, 2026, 08:01 AM

Optimi Health Secures Ibogaine Supply, Begins Finished Drug Product Development

AI Summary

Optimi Health Corp. announced it has secured a supply of naturally derived ibogaine and will commence finished drug product development. The company plans to develop 50mg and 100mg encapsulated dosages at its GMP facility in British Columbia. This initiative aligns with recent US executive orders prioritizing psychedelic therapies like ibogaine for accelerated FDA review and expanded patient access, particularly for conditions such as PTSD and opioid use disorder.

Key Highlights

Optimi Health has secured naturally derived ibogaine in both hydrochloride (HCl) and freebase form.
Finished drug product development for ibogaine is set to begin this summer at Optimi's GMP facility.
Planned dosage sizes for the ibogaine product are 50mg and 100mg in encapsulated format.
The company is developing its ibogaine product at its wholly owned GMP facility, also used for psilocybin and MDMA.
Ibogaine is being investigated for potential treatment of PTSD, opioid use disorder, and traumatic brain injury.

View SEC Filing

OPTH

Pharmaceutical Preparations

Optimi Health Corp.

Price Impact